Clinical Trials
Several clinical trials evaluate 2'-Hydroxy-4'-methylacetophenone across diverse therapeutic domains, including stage I–IV uterine corpus carcinoma, Lynch syndrome, acute kidney injury, contrast-induced nephropathy, clavicle fractures, mitral valve regurgitation, and mental health wellness. Spanning Early Phase 1, Not Applicable, and unspecified trial phases, these studies are sponsored by academic institutions and research cooperatives, including the National Cancer Institute and various university medical centers. Currently, overall trial recruitment statuses are recorded as not yet recruiting, withdrawn, or suspended.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01199250 | Not yet recruiting | Lynch Syndrome|Recurrent Uterine Corpus Carcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer |
Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
2100-01 | -- |
| NCT04598516 | Withdrawn | Acute Kidney Injury (Nontraumatic)|Contrast-induced Nephropathy|Renal Insufficiency |
Maastricht University Medical Center |
2097-11-01 | -- |
| NCT05454306 | Suspended | Clavicle Fracture |
University of Minnesota |
2028-01-09 | Not Applicable |
| NCT04795856 | Not yet recruiting | Mitral Valve Regurgitation |
University of Alabama at Birmingham |
2027-06-18 | Early Phase 1 |
| NCT06359262 | Not yet recruiting | Mental Health Wellness 1 |
Karolinska Institutet |
2027-01-01 | Not Applicable |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- 2'-Hydroxy-4'-methylacetophenone Stock Solution
- 2'-Hydroxy-4'-methylacetophenone Storage
- 2'-Hydroxy-4'-methylacetophenone Stability
- 2'-Hydroxy-4'-methylacetophenone Molecular Weight
- 2'-Hydroxy-4'-methylacetophenone SMILES
- 2'-Hydroxy-4'-methylacetophenone CAS Number
- 2'-Hydroxy-4'-methylacetophenone Chemical Structure (2D and 3D)
- 2'-Hydroxy-4'-methylacetophenone SDS|MSDS